347 476
Table 1 – Baseline clinicopathologic data on study cohorts
Unmatched cohort
Matched cohort
Radical treatment
ADT
p
value
Radical treatment
ADT
p
value
N
= 750
N
= 17 602
N
= 575
N
= 575
Median (IQR)
Median (IQR)
Median (IQR)
Median (IQR)
Follow-up time for alive individuals (yr)
4.9 (2.4–8.6)
4.5 (2.4–7.1)
0.002
5.2 (2.7–9.0)
4.5 (2.5–7.3)
0.02
Year of diagnosis
2004 (2000–2008)
2002 (1999–2005)
<
0.001
2004 (2000–2007)
2004 (2000–2007)
0.6
Age at diagnosis (yr)
64 (60–69)
76 (70–82)
<
0.001
65 (61–69)
66 (62–70)
0.1
PSA (ng/ml)
66 (57.0–86)
150 (81–430)
<
0.001
66 (57-85.0)
73 (61–91)
<
0.001
n
%
n
%
n
%
n
%
Clinical stage
<
0.001
1
cT1
193
26
1374
7.8
116
20
116
20
cT2
245
33
3836
22
188
33
188
33
cT3
304
41
9404
53
267
46
267
46
cT4
8
1.1
2988
17
4
0.7
4
0.7
N stage
<
0.001
<
0.001
cN0
434
58
226
1.3
340
59
19
3.3
cNX
290
39
16 755
95
215
37
488
85
cN1
26
3.5
621
3.5
20
3.5
68
12
M stage
<
0.001
<
0.001
cM0
598
80
3750
21
456
79
456
79
cMX
142
19
6786
39
109
19
71
12
cM1
10
1.3
7066
40
10
1.7
48
8.3
Gleason or WHO stage
<
0.001
1
6 or WHO 1
180
24
2116
12
115
20
115
20
7 or WHO 2
363
48
6999
40
286
50
286
50
8 or WHO 3
207
28
8487
48
174
30
174
30
PSA
<
0.001
0.5
50–100
629
84
6385
36
487
85
478
83
>
100
121
16
11217
64
88
15
97
17
Charlson comorbidity index
<
0.001
1
0
608
81
10282
58
489
85
489
85
1
87
12
3606
21
61
11
61
11
2
37
4.9
2013
11
19
3.3
19
3.3
3
18
2.4
1701
9.7
6
1.0
6
1.0
IQR = interquartile range; PSA = prostate-specific antigen; WHO = World Health Organization.
Left hand columns—unmatched cohort of radically treated and androgen deprivation patients with PSA
>
50 (
n
= 18 352); right hand columns—cohort of radically treated and androgen deprivation patients with PSA
>
50 frequency matched by PSA, clinical stage, M stage, tumor grade, Charlson comorbidity index, age, and year of diagnosis (
n
= 1150).
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 4 5 – 3 5 1
347